HCPLive Network

Collagenase Clostridium Histolyticum Tolerable in Peyronie's Disease

FRIDAY, April 26 (HealthDay News) -- For patients with Peyronie's disease, treatment with collagenase clostridium histolyticum (CCH) intralesional injections is efficacious and tolerable, according to research published online Feb. 1 in The Journal of Urology.

Martin Gelbard, MD, from the Urology Associates Medical Group, in Burbank, CA, and colleagues examined the clinical efficacy and safety of CCH intralesional injections among patients with Peyronie's disease (417 and 415 patients in Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies [IMPRESS] I and II, respectively). CCH injections were given through a maximum of four treatment cycles, each separated by six weeks, with two injections per cycle.

Based on meta-analysis of data from the two studies, the researchers found that patients treated with CCH experienced a mean 34 percent improvement in penile curvature deformity, compared with a mean 18.2 percent improvement seen in placebo-treated individuals (P < 0.0001). In CCH-treated versus placebo-treated individuals, the mean change in Peyronie's disease bother score was significantly improved. There were three corporal rupture serious adverse events, all of which were repaired surgically.

"The IMPRESS I and II studies support the clinical efficacy and safety of CCH treatment for both the physical and psychological aspects of Peyronie's disease," the authors write.

Several authors disclosed financial ties to Auxilium Pharmaceuticals, which funded the study and manufactures and markets CCH.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
Medical patients sometimes hear what we say skeptically, but Americans in general will believe any darn thing.
Bristol-Myers Squibb announced today the US Food and Drug Administration (FDA), had granted approval for Evotaz tablets in combination with other antiretroviral agents for an innovative treatment option for adults suffering from HIV-1 infection – delivering proven suppression through 48 weeks.
Researchers have found that menopause typically begins 2 to 4 years earlier in women with high levels of certain chemicals found in household items, personal care products, plastics, and the environment, compared to women with lower levels of the chemicals. The study was published online Jan. 28 in PLOS ONE.
More Reading